<DOC>
	<DOCNO>NCT00098332</DOCNO>
	<brief_summary>RATIONALE : Forodesine ( BCX-1777 ) may stop growth cancer cell block enzymes necessary growth . PURPOSE : Phase I trial study effectiveness BCX-1777 treating patient refractory stage IIA , stage IIB , stage III , stage IVA , stage IVB cutaneous T-cell lymphoma .</brief_summary>
	<brief_title>Forodesine ( BCX-1777 ) Treating Patients With Refractory Stage IIA , Stage IIB , Stage III , Stage IVA , Stage IVB Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy forodesine ( BCX-1777 ) patient refractory stage IIA-IVB cutaneous T-cell lymphoma . - Determine pharmacokinetics pharmacodynamics drug patient . OUTLINE : This open-label , multicenter study . Patients receive oral forodesine ( BCX-1777 ) daily day 1-28 . Courses may repeat absence disease progression unacceptable toxicity . Patients follow periodically . PROJECTED ACCRUAL : Not specify .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cutaneous Tcell lymphoma Refractory prior treatment Stage IIA , IIB , III , IVA , IVB disease Measurable disease PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Not specify Hepatic AST and/or ALT ≤ 3 time upper limit normal Hepatitis B and/or hepatitis C negative Renal Creatinine clearance ≥ 40 mL/min Immunologic Human Tcell lymphotrophic virus type I ( HTLVI ) negative HIV negative No active serious infection control antibiotic Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known impair absorption gastrointestinal tract No illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 21 day since prior chemotherapy recover Endocrine therapy Concurrent topical corticosteroid allow provided patient remain stable dose Radiotherapy No concurrent radiotherapy Surgery Not specify Other More 30 day since prior investigational agent recover No concurrent tan bed use No concurrent therapy cutaneous Tcell lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
</DOC>